American Century Companies’s ADMA Biologics ADMA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$1.9M Sell
226,518
-4,562,493
-95% -$41.6M ﹤0.01% 2212
2026
Q1
$43.1M Sell
4,789,011
-409,368
-8% -$6.46M 0.02% 816
2025
Q4
$94.8M Buy
5,198,379
+502,456
+11% +$8.47M 0.05% 436
2025
Q3
$68.8M Buy
4,695,923
+84,934
+2% +$1.46M 0.04% 569
2025
Q2
$84M Buy
4,610,989
+358,627
+8% +$7.31M 0.05% 433
2025
Q1
$84.4M Buy
4,252,362
+478,800
+13% +$8.28M 0.05% 388
2024
Q4
$64.7M Sell
3,773,562
-436,091
-10% -$8.2M 0.04% 518
2024
Q3
$84.2M Sell
4,209,653
-1,844,664
-30% -$28.7M 0.05% 392
2024
Q2
$67.7M Sell
6,054,317
-1,074,194
-15% -$9.01M 0.04% 447
2024
Q1
$47M Buy
7,128,511
+315,820
+5% +$1.73M 0.03% 582
2023
Q4
$30.8M Buy
6,812,691
+1,920,568
+39% +$7.11M 0.02% 702
2023
Q3
$17.5M Buy
4,892,123
+840,761
+21% +$3.24M 0.01% 850
2023
Q2
$14.9M Buy
4,051,362
+2,936,092
+263% +$10.9M 0.01% 888
2023
Q1
$3.68M Buy
+1,115,270
New +$3.86M ﹤0.01% 1368

Other funds holding ADMA

American Century Companies's ADMA Position: Q2 2026 in Review

American Century Companies reduced its ADMA Biologics (ADMA) stake by 95% in Q2 2026, selling an estimated $41.6M and leaving 226,518 shares worth $1.9M. The position accounts for ﹤0.01% of the portfolio, ranked #2212.

American Century Companies first reported a position in ADMA in Q1 2023 and has held it in 14 quarters since. The position peaked at $94.8M in Q4 2025. 323 funds tracked by Wall St. Rank hold ADMA as of Q2 2026.

  • American Century Companies held 226,518 shares of ADMA Biologics worth $1.9M as of Q2 2026.
  • American Century Companies sold 4,562,493 ADMA Biologics shares in Q2 2026, an estimated $41.6M.
  • ADMA Biologics made up ﹤0.01% of American Century Companies's portfolio in Q2 2026, its #2212 holding.
  • American Century Companies first reported a position in ADMA Biologics in Q1 2023 and has held it in 14 quarters since.
  • American Century Companies's ADMA Biologics position peaked at $94.8M in Q4 2025.
  • 323 funds tracked by Wall St. Rank held ADMA Biologics as of Q2 2026.

Based on American Century Companies's 13F filing for Q2 2026, filed 12 Aug 2026.